GoldenGolden
Advanced Search
Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals is an antibiotics company targeting multi-drug resistant bacterial infections founded in 2006.

Tetraphase Pharmaceuticals, Inc., utilizes their proprietary chemistry technology to create tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the WHO.

Timeline

June 1, 2010
Tetraphase Pharmaceuticals raises a $45,000,000 series C round from Skyline Ventures.
August 7, 2008
Tetraphase Pharmaceuticals raises a $15,000,000 series A round from Fidelity Ventures and Skyline Ventures.

Funding rounds

People

Name
Role
LinkedIn

Joe Newman

Employee

Sergey Izmailyan

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
June 4, 2020
BioSpace
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals - read this article along with other careers information, tips and advice on BioSpace
May 27, 2020
BioSpace
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase - read this article along with other careers information, tips and advice on BioSpace
Andrew Jacobs
December 25, 2019
www.nytimes.com
First Big Pharma fled the field, and now start-ups are going belly up, threatening to stifle the development of new drugs.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.